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Bladder cancer is the fourth most common cancer in men and the
tenth in women, with approximately 12 500 new cases in the UK
(Cancer Research Campaign Factsheet 9.1, 1997). Stage and grade
as measures of the depth of invasion into the bladder wall and
degree of differentiation of the tumour, respectively, are currently
the most widely used indicators of prognosis. Other known
adverse risk factors include the presence of multiple tumours at
presentation (Parmar et al, 1989), the recurrence of tumours at 3
months post-cystoscopy (Reading et al, 1995) and p53 mutations
(Esrig et al, 1994; Caliskan et al, 1997).
For patients presenting with superficial bladder cancer (pTa and
pT1) the prognosis is good. Although recurrences occur in approx-
imately 70% of patients, only 10–15% progress to muscle-
invasive disease (Hudson and Catalona, 1996). However, there is
a need for regular monitoring to identify patients at risk of recur-
rence or progression as early as possible so that appropriate
therapy can be initiated promptly. To date, there are no established
tumour markers available, although several have been investigated
in preliminary studies with promising results in terms of diag-
nostic or prognostic use. These include bladder-tumour associated
analyte (BTA; Sarosdy et al, 1995; D’Hallewin and Baert, 1996;
Leyh et al, 1997), nuclear matrix protein 22 (NMP22; Soloway
et al, 1996), telomerase activity (Kinoshita et al, 1997; Yoshida
et al, 1997), Ki-67 antigen and p53 protein expression (Tsuji et al,
1997), microsatellite analysis (Mao et al, 1996; Steiner et al, 1997)
and matrix metalloproteinases, their inhibitors and activators
(Gohji et al, 1998; Kanayama et al, 1998).
Cadherins are Ca2+-dependent homotypic adhesion molecules
essential for maintaining intercellular adhesion (Takeichi, 1990).
E-cadherin (120 kDa) is mainly involved in epithelial cell–cell
interactions with loss being associated with increased invasiveness
and decreased differentiation in a variety of malignancies
including breast, prostate and gastric carcinoma (Takeichi, 1993).
Decreased, heterogeneous or absent expression of membrane-
associated E-cadherin has been reported in malignant bladder
tumours, with abnormal expression correlating with increasing
grade and invasiveness (Bringuier et al, 1993; Otto et al, 1994;
Lipponen and Eskelinen, 1995; Ross et al, 1995; Syrigos et al,
1995) and associated with reduced survival (Bringuier et al, 1993;
Syrigos et al, 1995). Similarly in patients with pTa or pT1 bladder
tumours, abnormal expression of E-cadherin has been associated
with more rapid progression and reduced survival (Otto et al,
1994; Lipponen and Eskelinen 1995).
Although changes in expression of E-cadherin may account for
changes in cell invasiveness, additional mechanisms may also
contribute to altered function of this adhesion molecule (Hiraguri
et al, 1998). Point mutations in the calcium binding sites (Ozawa
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Summary Reduced expression of the adhesion molecule E-cadherin has been associated with increased invasiveness and poorer survival in
patients with bladder cancer. We have examined soluble E-cadherin (sE-cadherin) and total protein concentrations in urine from patients with
bladder cancer (n = 34), non-neoplastic benign urological diseases (n = 14) and healthy controls (n = 21) to determine their diagnostic and
prognostic significance. Soluble E-cadherin concentrations of the cancer group were significantly higher (P < 0.001) than those of the controls
but the benign group was not significantly different from either the cancer group or the controls. When sE-cadherin concentrations were
adjusted for creatinine, similar but more statistically significant results were obtained and the benign group was significantly elevated
compared with the controls (P < 0.01). No differences were apparent between the invasive (pT1–4) and non-invasive (pTa) cancers. Urinary
total protein concentrations in the cancer group were significantly higher than the controls (P < 0.001) and the benign group (P < 0.05)
although no difference was seen between the benign group and patients with non-invasive (pTa) cancer or between the benign group and
controls. When expressed as the protein/creatinine index, results were similar but more statistically significant and a significant difference was
seen between invasive and non-invasive cancers (P < 0.01). Only the protein/creatinine index correlated significantly with stage of the tumour
(P < 0.01). It is concluded that urinary sE-cadherin measurements are of no greater value than urinary total protein.
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University of Kentucky Medical Center, USAet al, 1990; Kanai et al, 1994), loss of heterozygosity (Becker and
Hofler, 1995), hypermethylation of the promoter region (Yoshuira
et al, 1995), aberrant function of the catenins (Shimoyama et al,
1992) or increased shedding of E-cadherin from the cell
membrane (Matsuura et al, 1992), have all been proposed as
contributory mechanisms for impairment of adhesive function.
Soluble forms of several adhesion molecules have been
identified (Gearing and Newman, 1993), and a soluble form of
E-cadherin (sE-cadherin; 80 kDa) has been shown to be shed by
the MCF-7 breast cancer line (Damsky et al, 1983). Proteolytic
cleavage of E-cadherin from the cell surface may account for the
soluble form (Matsuura et al, 1992), which has been found in
serum (Katayama et al, 1994a; Griffiths et al, 1996) and in urine
(Katayama et al, 1994b; Banks et al, 1995) with elevated levels
in patients with a variety of cancers. Following the recent finding
of elevated serum sE-cadherin concentrations in patients with
bladder tumours (Griffiths et al, 1996), we have performed a
preliminary cross-sectional study measuring urinary sE-cadherin
levels in patients with bladder cancer, non-neoplastic conditions
and healthy volunteers and compared these with urinary total
protein levels to establish whether such measurements may be of
use clinically for diagnostic or monitoring purposes.
MATERIALS AND METHODS
Urine samples were collected over a period of several months
from patients attending the urology ward for investigations prior to
treatment. Details of the patient and control groups are provided in
Table 1. Aprotinin was added (final concentration 100 KIU ml–1)
and the samples were centrifuged at 1500 g for 10 min to remove
cellular debris before being aliquoted and stored at –70°C until
assayed. Additional samples were collected from healthy volun-
teers. Histological specimens were reviewed independently and
blindly by a single pathologist and all tumour sections were staged
according to the TNM classification (Hermanek and Sobin, 1987)
and graded according to the WHO criteria (Mostofi et al, 1973).
The tumour stage and grade of the patients with bladder cancer are
shown in Table 2. The benign group consisted of two patients with
inflammatory conditions of the bladder, four with benign prostatic
hypertrophy, two with kidney stones, one with moderate dysplasia
and five were patients who had previously been treated for non-
invasive malignancies but currently had normal biopsies.
Soluble E-cadherin concentrations were determined using a
commercially available enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (Takara
Shuzo, Japan). This assay is based on the capture of sE-cadherin
using a solid-phase adsorbed monoclonal antibody followed by
subsequent detection using a labelled second monoclonal antibody
to E-cadherin, with a detection limit of < 50 ng ml–1. Urinary
protein concentrations were determined by standard automated
analysis with a Bayer Axon analyser using pyrogallol red reagent
(0.05 mM; Sigma, UK) with a timed end-point method and stan-
dardization against human albumin (Sigma). Creatinine concentra-
tions in urine were measured by the Jaffe method (Rock et al,
1986) using the Bayer Axon analyser. Both sE-cadherin and total
protein concentrations were adjusted for creatinine concentration
and expressed as a sE-cadherin/creatinine index or protein/
creatinine index, respectively, calculated as protein (g l–1) ´ 10 000
divided by creatinine (mmol l–1) with units of ´ 10 g mmol–1 to be
in accordance with previous studies (Dyson et al, 1992; Mitchell
et al, 1993).
Urine samples from 12 controls and 21 of the patients with
bladder tumours were analysed by Western blotting following
electrophoresis on 8% sodium dodecyl sulphate (SDS)
polyaryclamide gels under reducing conditions, as previously
described (Banks et al, 1995).
Statistical analysis
Statistical analysis was carried out using SPSS-PC (SPSS Inc,
Illinois, USA). As the data were found to be non-normally distrib-
uted using the Shapiro–Wilks and K–S (Lilliefors) tests, the non-
parametric Mann–Whitney test and Spearman’s correlation were
used. Differences were judged to be statistically significant if
P < 0.05.
RESULTS
A total of 69 samples were assayed. As the ages between the
normal (healthy and benign controls) and malignant groups
differed significantly (P < 0.05), the relationship of the assayed
parameters with age was examined but no correlations were found.
Considerable overlap was seen between the groups regarding
urinary sE-cadherin concentrations (Figure 1A) with the only
statistically significant differences being seen between the control
(range 24.9–1437, median 582) and neoplastic group, whether the
latter was examined as a whole (range 12–3813, median 1272.5)
or subdivided into the non-invasive (pTa; range 12–3812, median
1284) and invasive (pT1–4; range 97.7–2327.2, median 1551)
cancers (P < 0.001, P < 0.01, P < 0.01 respectively). When
adjusted for creatinine concentration (Figure 1B), the difference
between the control (range 0.058–1.481, median 0.516) and
neoplastic groups (whole: range 0.043–6.0, median 1.536; pTa:
range 0.043–5.271, median 1.477; pT1–4: range 0.026–6.0,
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Table 1 Details of the sample groups
Healthy Benign Cancer Total
controls group group number
Total number 21 14 34 69
Male 10 9 21 40
Female 11 5 13 29
Age range (years) 30–82 16–85 44–89 16–89
Mean age (years) 56.1 65.9 70.8
Table 2 Stage/grade of bladder tumours
Number of
patients
Tumour grade
G1 4
G2 17
G3 13
Tumour stage
pTa 23
pT1 3
pT2 0
pT3 7
pT4 1median 1.939) became more significant (P = 0.0001, P < 0.001
and  P < 0.001 respectively) and additionally a significant
difference (P < 0.01) was seen between the control (range
5.8–148.1, median 51.6) and benign group (range 24.1–282.6,
median 157.3). However, there was no apparent difference
between the benign group and patients with cancer, or between
patients with non-invasive (pTa) or invasive disease (pT1–4).
When the urinary total protein concentrations were analysed
(Figure 2A), considerable overlap between groups was again seen,
but patients with tumours (range 0.03–6.38, median 0.255) had
significantly higher concentrations than those of the control group
(range 0.01–0.72, median 0.07) (P < 0.001) or the benign group
(range 0.02–7.75, median 0.085) (P < 0.05). However, when the
neoplastic group was subdivided into invasive (pT1–4) (range
0.04–6.38, median 0.4) and non-invasive (pTa) cases (range
0.02–2.19, median 0.22), only the protein concentrations of the
invasive sub-group were significantly higher than those of the
benign group (P < 0.05). No significant difference was seen
between the invasive and non-invasive groups or between the
benign and control groups. When the protein/creatinine index was
used (Figure 2B), similar but more significant differences were
seen between the groups (healthy controls: range 20.8–454.6,
median 90.9; benign controls: range 27.8–10 616.4, median 113.2;
neoplastic group: range 59.7–4524.8, median 263.6) and, in
addition, a significant difference (P < 0.01) was seen between
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Figure 1 (A) Urinary sE-cadherin levels (mg l–1) and (B) urinary sE-
cadherin/creatinine index versus patient group; — represents the median
value
Figure 2 (A) Urinary total protein (g l–1) and (B) protein/creatinine index
versus patient group;— represents the median value
Table 3 Numbers of urine samples with each form of sE-cadherin as
detected by Western blotting
sE-cadherin Normal
controls Cancer group (n = 21)
(n = 12)
Grade Stage
G1 G2 G3 pTa pT1 pT2 pT3 pT4
No band 1 0 1 1 1 0 0 1 0
80 kDa only 8 1 9 5 11 1 0 2 1
80 and 65 kDa 3 0 1 3 2 1 0 1 0non-invasive (range 59.7–4206.9, median 214.3) and invasive
cancers (range 153.9–4524.8, median 776).
No significant correlation was found between sE-cadherin
concentrations (absolute or following adjustment for creatinine) or
total protein and tumour stage or grade. However, the protein/
creatinine index correlated significantly with tumour stage
(P < 0.01) and just failed to reach a significant correlation with
tumour grade (P < 0.06).
A main sE-cadherin band of 80–85 kDa was detected by
Western blotting (as shown previously; Banks et al, 1995) in 30
out of 33 samples (Table 3) with a further additional band of
65–70 kDa apparent in 20–25% of both the control and patient
samples. No bands were detected in the blots incubated with an
irrelevant primary antibody as a non-specific binding control.
DISCUSSION
Loss or decreased expression of the adhesion molecule E-cadherin
correlating with tumour progression has now been shown
immunohistochemically in many tumour types (reviewed by
Takeichi, 1993) illustrating the important role of this molecule in
maintaining normal epithelial cohesion. Earlier studies showing
the occurrence of a soluble form of this molecule in cell culture
systems in vitro (Damsky et al, 1983) have led to the search for
and subsequent finding of soluble forms in biological fluids in
vivo with the hope that such a molecule may in some way reflect
tumour progression and hence lend itself to being a tumour
marker. Following our previous observations of the presence of
sE-cadherin in urine (Banks et al, 1995), we have now demon-
strated that urinary sE-cadherin concentrations are significantly
increased in bladder cancer patients compared to normal controls,
whether expressed as an absolute concentration or following
adjustment for creatinine concentration.
The exact mechanism of production of the soluble form of
E-cadherin is not known. Alternatively spliced forms of some
adhesion molecules such as P-selectin have been described which
lack the transmembrane region (Gearing and Newman, 1993) but
similarly generated transcripts have not been described as yet for
soluble E-cadherin. Proteolytic cleavage is also known to be
important in the generation of many soluble molecules and studies
have shown such a mechanism can occur for soluble E-cadherin
(Damsky et al, 1983; Katayama et al, 1994a) with the intact mole-
cule of 110–120 kDa being proteolytically digested to yield an
80 kDa molecule as found in this study. This may occur to a
limited extent during normal cellular turnover but would be
expected to be increased in conditions where protease release is
enhanced. As such, significant differences in sE-cadherin concen-
trations would be expected between the non-invasive and invasive
subgroups. The apparent absence of any such difference may be
due to the relatively small number of patients in this study,
although considerable overlap is seen between the groups. Given
the overlap between groups, and the lack of correlation with stage
or grade, the clinical use is likely to be limited.
The existence of two soluble forms of E-cadherin in urine
(65 kDa and 80 kDa) as detected by Western blotting was
described in our original study (Banks et al, 1995) and confirmed
in this study. The significance of the two forms is unclear with the
simultaneous presence of both forms being seen in 20–25% of
both controls and patients with bladder cancer. It is likely that
proteolysis accounts for the two fragments of the protein but this
needs to be confirmed. The proteolysis is unlikely to have
occurred in vitro as samples were collected containing protease
inhibitors. It is also not known whether both these fragments are
detected by the immunoassay used in this study which may result
in underestimation of the sE-cadherin concentration in some
samples. Soluble E-cadherin molecules with electrophoretic
mobilities ranging from 75 to 85 kDa have been reported before in
urine samples from patients with benign and malignant conditions
(Katayama et al, 1994b).
The only other study which has examined sE-cadherin concen-
trations in patients with bladder cancer analysed serum samples
from patients at presentation (Griffiths et al, 1996) and found
significantly higher concentrations than controls in patients with
high-grade tumours or muscle-invasive disease. These are similar
to our findings using urine samples, although we detected a
significant difference between the control and non-invasive
groups. No apparent difference was seen between the non-invasive
and invasive groups in either study and neither did serum
sE-cadherin concentration correlate with abnormal E-cadherin
expression on the surface of bladder tumours (Griffiths et al,
1996). This does not support an increased rate of shedding as
being the sole mechanism for the decreased cellular expression in
cancer.
Increased urinary protein excretion is a relatively common
finding in patients with bladder cancer, with concentration being
related to tumour size but not grade and a significant reduction
being seen following successful treatment (Johansson, 1975;
Johansson and Kistner, 1975; Hemmingsen et al, 1981).
Qualitative studies have shown the increased concentration of a
number of proteins including IgG, IgA, transferrin, a1-acid glyco-
protein, haptoglobin, fibrinogen, a1-antitrypsin and a2-macroglob-
ulin, a similar profile also being seen in infection (Johansson,
1975; Johansson and Kistner, 1975; O’Brien et al, 1980, 1981).
The finding of a predominantly glomerular proteinuria decreasing,
but not returning to normal, after successful treatment or urinary
diversion, particularly in higher grade tumours where it may be of
predictive value (Hemmingsen et al, 1981), has been proposed
to be associated with the finding of glomerular deposition of
antigen–antibody complexes in urothelial malignancies (Jones
et al, 1975). Additionally, some proteins may be present due to
leakage from the plasma, possibly caused by tumour neovascular-
ization, invasion or an inflammatory response, or alternatively
may be derived from the tumour itself as a result of increased
cellular turnover. Examining total protein concentration provides
limited information due to its lack of tumour-specificity, being
elevated, for example, by infection. However, in this study at least,
total protein appears to be superior to sE-cadherin as a ‘marker’ in
bladder cancer and is considerably cheaper to assay. Although the
protein/creatinine ratio is significantly different between groups,
the considerable overlap prohibits its use diagnostically. It is
possible that longitudinal measurements may be of use on an indi-
vidual patient basis as an initial follow-up screen but additional
factors producing an increase in protein concentrations such as
infection would need to be excluded.
Expressing the urinary results following adjustment for creati-
nine concentration is probably the more valid reflection of overall
sE-cadherin or total protein release as it takes into account the
variations in the renal function and hydration state of patients and
when evaluated for total protein measurements has been shown to
allow the use of single sample analysis as an adequate substitute
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et al, 1993). Whether there is a diurnal variation on sE-cadherin
concentration, and thus an optimal time for sample collection other
than the mid-morning samples used in this study, was not estab-
lished. The presence of intercurrent renal disease should also be
taken into account due to its effects on the creatinine and hence the
creatinine adjusted parameters. In this study, none of our patients
were being treated for renal disease although six patients had
mildly elevated serum creatinine concentrations.
Although significant differences were found between normal
control and malignant groups, the overlap in the values between
these groups and also those of the benign group indicate that
measurement of urinary sE-cadherin concentrations alone could
not be used as the basis for screening for malignant disease.
However, in the light of the earlier results showing patients at
risk of early relapse had significantly elevated levels of serum
sE-cadherin at presentation (Griffiths et al, 1996), this should be
explored further in a longitudinal study using both serum and urine
samples. In addition, the use of urinary total protein should be
explored further as it appears to be superior to sE-cadherin in its
discriminatory capacity and would be more cost effective.
REFERENCES
Banks RE, Porter WH, Whelan P, Smith PH and Selby PJ (1995) Soluble forms of
the adhesion molecule E-cadherin in urine. J Clin Path 48: 179–180
Becker KF and Hofler H (1995) Frequent somatic allelic inactivation of the
E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 87: 1082–1084
Bringuier PP, Umbas R, Schaafsma HE, Karthaus HFM, Debrugne FMJ and
Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with
poor survival in patients with bladder tumours. Cancer Res 53: 3241–3245
Caliskan M, Turkeri LN, Mansuroglu B, Toktas G, Aksoy B, Uncluer E and Akdas
A (1997) Nuclear accumulation of mutant p53 protein: a possible predictor of
failure of intravesical therapy in bladder cancer. Br J Urol 79: 373–377
Cancer Research Campaign Factsheet 9.1 (1997) Cancer Research Campaign:
London
Damsky CH, Richa J, Solter D, Knudsen K and Buck CA (1983) Identification and
purification of a cell surface glycoprotein mediating intercellular adhesion in
embryonic and adult tissue. Cell 34: 455–466
D’Hallewin MA and Baert L (1996) Initial evaluation of the bladder tumour antigen
test in superficial bladder cancer. J Urol 155: 475–476
Dyson EH, Will EJ, Davidson AM, O’Malley AH, Shepard HT and Jones RG (1992)
Use of the urinary protein creatinine index to assess proteinuria in renal
transplant patients. Nephrol Dial Transplant 7: 450–452
Esrig D, Elmajian D, Groshen S, Freeman J, Stein J, Chen SC, Nichols P, Skinner D,
Jones P and Cote R (1994) Accumulation of nuclear p53 and tumour
progression in bladder cancer. N Engl J Med 331: 1259–1264
Gearing AJH and Newman W (1993) Circulating adhesion molecules in disease.
Immunol Today 14: 506–512
Gohji K, Fujimoto N, Ohkawa J, Fujii A and Nakajima M (1998) Imbalance between
serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence
of urothelial cancer. Br J Cancer 77: 650–655
Griffiths TRL, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CHW,
Shenton BK, Neal DE and Mellon JK (1996) Cell adhesion molecules in
bladder cancer: soluble serum E-cadherin correlates with predictors of
recurrence. Br J Cancer 74: 579–584
Hemmingsen L, Rasmussen F, Skaarup P and Wolf H (1981) Urinary protein profiles
in patients with urothelial bladder tumours. Br J Urol 53: 324–329
Hermanek P and Sobin LH (eds) (1987) UICC TNM Classification of Malignant
Tumours, 4th edn, pp. 65–67. Springer Verlag: Berlin
Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N,
Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D and Gray J (1988)
Mechanisms of inactivation of E-Cadherin in breast cancer cell lines. Cancer
Res 58: 1972–1977
Hudson MA and Catalona WJ (1996) Urothelial tumours of the bladder, upper tracts
and prostate. In Adult and Paediatric Urology, Gillenwater JY, Grayhack JT,
Howards SS and Duckett JW (eds), pp. 643–694. Mosby: St Louis, MO
Johansson B (1975) Urinary protein patterns in patients with uroepithelial tumours.
Scand J Urol Nephrol 9: 221–225
Johansson B and Kistner S (1975) Proteinuria in patients with uroepithelial tumours
with special regard to tumour size, clinical staging and grade of malignancy.
Scand J Urol Nephrol 9: 45–49
Jones LW, Levin A and Fudenberg HH (1975) Glomerular antigen complexes
associated with transitional cell carcinoma. Surg Gynecol Obstet 140: 896–898
Kanai Y, Oda T, Tsuda H, Ochiai A and Hirohashi S (1994) Point mutation of the
E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res
85: 1035–1039
Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M and Kagawa S
(1998) Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of
metalloproteinase-2 expression in bladder cancer. Cancer 82: 1359–1366
Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M and Kato I (1994a)
Soluble E-cadherin fragments increased in circulation of cancer patients.
Br J Cancer 69: 580–585
Katayama M, Hirai S, Yasumoto M, Nishikawa K, Nagata S, Otsuka M, Kamihagi K
and Kato I (1994b) Soluble fragments of E-cadherin cell adhesion molecule
increase in urinary excretion of cancer patients, potentially indicating its
shedding from epithelial tumour cells. Int J Oncol 5: 1049–1057
Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H,
Terachi T and Yoshida O (1997) Detection of telomerase activity in exfoliated
cells in urine from patients with bladder cancer. J Natl Cancer Inst 89: 724–730
Leyh H, Hall R, Mazeman E and Blumenstein B (1997) Comparison of the BARD
BTA test with voided urine and bladder wash cytology in the diagnosis and
management of cancer of the bladder. Urology 50: 49–53
Lipponen PK and Eskelinen MJ (1995). Reduced expression of E-cadherin is related
to invasive disease and frequent recurrence in bladder cancer. J Cancer Res
Clin Oncol 121: 303–308
Mao L, Schoenberg M, Scicchitano M, Erozan Y, Merlo A, Schwab D and Sidransky
D (1996) Molecular detection of primary bladder cancer by microsatellite
analysis. Science 271: 659–662
Matsuura K, Kawanishi J, Fujii S, Imamura M, Hiranos S, Takeichi M and Niitsu Y
(1992) Altered expression of E-cadherin in gastric cancer tissue and
carcinomatous fluid. Br J Cancer 66: 1122–1130
Mitchell S, Sheldon T and Shaw A (1993) Quantification of proteinuria: a re-
evaluation of the protein/creatinine ratio for elderly subjects. Age Ageing 22:
443–449
Mostofi FK, Sobin LH and Torloni H (1973) Histological typing of urinary bladder
tumours. In International Histological Classification of Tumours, 10: World
Health Organization: Geneva
O’Brien P, Gozzo J, Cronin W and Monaco A (1980) Qualitative analysis of
proteinuria associated with bladder cancer. Invest Urol 17: 28–32
O’Brien P, Gozzo JJ and Monaco AP (1981) Urinary proteins as biological markers:
bladder cancer diagnosis versus urinary tract infection. J Urol 124: 802–803
Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rubben H and Raz A (1994)
Inverse relation of E-cadherin and autocrine motility factor receptor expression
as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:
3120–3123
Ozawa M, Engel J and Kemler R (1990) Single amino acid substitutions in one Ca2+
binding site of uvomorulin abolish adhesive function. Cell 63: 1033–1038
Parmar MKB, Freedman LS, Hargreave TB and Tolley DA (1989) Prognostic factors
for recurrence and follow-up policies in the treatment of superficial bladder
cancer: report from the British Medical Research Council Subgroup on
Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142:
284–288
Reading J, Hall RR and Parmar MKB (1995) The application of a prognostic factor
analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol 75:
604–607
Rock RC, Walker WG and Jennings CD (1986) Nitrogen metabolites and renal
function. In Textbook of Clinical Chemistry, Tietz NW (ed), pp. 1254–1316.
WB Saunders: Philadelphia
Ross JS, Del Rosario AD, Figge HL, Sheehan C, Fisher HAG and Bui HX (1995)
E-cadherin expression in papillary transitional cell carcinoma of the urinary
bladder. Hum Pathol 26: 940–944
Sarosdy M, deVERE White R, Soloway M, Sheinfeld J, Hudson M, Schellhammer P,
Jarowenko M, Adams G and Blumenstein B (1995) Results of a multicentre
trial using the BTA test to monitor for and diagnose recurrent bladder cancer.
J Urol 154: 379–384
Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S and
Hirohashi S (1992) Cadherin dysfunction in a human cancer cell line: possible
involvement of loss of a-catenin expression in reduced cell–cell adhesiveness.
Cancer Res 52: 5770–5774
Soloway M, Briggman J, Carpinito G, Chodak G, Church P, Lamm D, Lange P,
Messing E, Pasciak R, Reservitz G, Rukstalis D, Sarosdy M, Stadler W, Thiel
R and Hayden C (1996) Use of a new tumour marker, urinary NMP22, in the
Urinary soluble E-cadherin in bladder cancer 277
British Journal of Cancer (1999) 80(1/2), 273–278 © Cancer Research Campaign 1999detection of occult or rapidly recurring transitional cell carcinoma of the
urinary tract following surgical treatment. J Urol 156: 363–367
Steiner G, Schoenberg MP, Linn JF, Mao L and Sidransky D (1997) Detection of
bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3:
621–624
Syrigos K, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J, Epenetos
A and Pignatelli M (1995). E-cadherin expression in bladder cancer using
formalin-fixed, paraffin-embedded tissues: correlation with histopathological
grade, tumour stage and survival. Int J Cancer 64: 367–370
Takeichi M (1990) Cadherins: a molecular family important in selective cell–cell
adhesion. Ann Rev Biochem 59: 237–252
Takeichi M (1993) Cadherins in cancer implications for invasion and metastasis.
Curr Opin Cell Biol 5: 806–811
Tsuji M, Kojima Y, Murakami Y, Kanayama H and Kagawa S (1997) Prognostic
value of Ki-67 antigen and p53 protein in urinary bladder cancer:
immunohistochemical analysis of radical cystectomy specimens. Br J Urol 79:
367–372
Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, Fellows G,
Goodison S, Tahara E and Tarin D (1997) Telomerase activity in bladder
carcinoma and its implication for noninvasive diagnosis by detection of
exfoliated cancer cells in urine. Cancer 79: 362–369
Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T and Hirohashi S (1995)
Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in
human carcinomas. Proc Natl Acad Sci USA 92: 7416–7419
278 AS Protheroe et al
British Journal of Cancer (1999) 80(1/2), 273–278 © Cancer Research Campaign 1999